Fauzia Jamal, Ghufran Ahmed, Mohammad Farazuddin, Ishrat Altaf, Saba Farheen, Qamar Zia, Asim Azhar, Hira Ahmad, Aijaz Ahmed Khan, Satyanarayana Somavarapu, Anshu Agrawal, Mohammad Owais
Therapeutics, based on small interfering RNA (siRNA), have demonstrated tremendous potential for treating cancer. However, issues such as non-specific targeting, premature degradation, and the intrinsic toxicity of the siRNA, have to be solved before they are ready for use in translational medicines. To address these challenges, nanotechnology-based tools might help to shield siRNA and ensure its specific delivery to the target site. Besides playing a crucial role in prostaglandin synthesis, the cyclo-oxygenase-2 (COX-2) enzyme has been reported to mediate carcinogenesis in various types of cancer, including hepatocellular carcinoma (HCC)...
February 27, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry